US$ 25.87
tirzepatide and afib GLP-1 receptor agonists, including semaglutide (Wegovy/Ozempic) (Mounjaro/Zepbound), are being recognized for benefits beyond blood sugar control and weight management. New real-world evidence suggests they may also play a role in Meta-Analysis Assessing the Effect of
Description
These differences limit the ability to make assumptions about the consistency of clinical benefit in older T2D populations at high CV risk

Clinical efficacy of bariatric surgery versus liraglutide in patients with type 2 diabetes and severe obesity: a 12-month retrospective evaluation

Weight loss itself reduces AFib burden: studies demonstrate that losing 10% of body weight significantly decreases arrhythmia frequency and symptom severity in overweight AFib patients

If you're on a GLP-1 medication, it's worth knowing that alcohol is high in calories and can cause blood sugar levels to spike and crash
